



FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1483.0340003/JMC/JSLAPPLICATION NO.  
10/772,445FIRST NAMED INVENTOR  
Upasani et al.FILING DATE  
February 6, 2004ART UNIT  
1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	3,748,331	06/24/1973	Cooke et al.			05/06/1971
	AB1	3,963,717	06/15/1976	Cooke et al.			03/10/1975
	AC1	5,284,957	02/08/1994	Huff			09/03/1992
	AD1	5,514,680	05/07/1996	Weber et al.			11/05/1993
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
PCU C	AL1	WO 94/13275	06/23/1993 4	WIPO			Yes
1	AM1						No
1	AN1						Yes
17	AO1						No
g	AP1						Yes
							No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	1	Anderson, B.A. et al., "Application of a Practical Biocatalytic Reduction to an Enantioselective Synthesis of the 5H-2,3-Benzodiazepine LY300164," <i>J. Am. Chem. Soc.</i> 117:12358-12359, American Chemical Society (1995)
AS	1	Buchan, A.M. et al., "Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia," <i>Neuroreport</i> 2:473-476, Lippincott, Williams & Wilkins (1991)
AT	1	Buchan, A.M. et al., "AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials Than NMDA Antagonists?" <i>Stroke Suppl. 1</i> 24:I-148-I-154, Lippincott, Williams & Wilkins (1993)

EXAMINER /Cecilia Jaisle/

DATE CONSIDERED 08/02/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.